10-Q 1 pets-20231231.htm 10-Q pets-20231231
0001040130--03-312024Q3falseP3YP3YP1YP1YP1Y0.333333333333333P1Y00010401302023-04-012023-12-3100010401302024-04-15xbrli:shares00010401302023-12-31iso4217:USD00010401302023-03-31iso4217:USDxbrli:shares00010401302023-10-012023-12-3100010401302022-10-012022-12-3100010401302022-04-012022-12-3100010401302022-03-3100010401302022-12-310001040130srt:ScenarioPreviouslyReportedMember2022-10-012022-12-310001040130srt:ScenarioPreviouslyReportedMember2022-04-012022-12-310001040130srt:ScenarioPreviouslyReportedMember2022-12-310001040130srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-12-310001040130srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-10-012022-12-310001040130srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-04-012022-12-310001040130srt:ScenarioPreviouslyReportedMember2022-03-310001040130srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-03-31pets:reporting_unit0001040130srt:MinimumMember2023-12-310001040130srt:MaximumMember2023-12-31pets:performanceObligation0001040130pets:MembershipFeesMember2023-12-310001040130pets:MembershipFeesMember2023-10-012023-12-310001040130pets:MembershipFeesMember2023-04-012023-12-310001040130pets:PetCareRxIncMember2023-04-012023-06-300001040130pets:MembershipFeesMember2023-04-012023-06-3000010401302023-06-300001040130pets:MembershipFeesMember2023-07-012023-09-3000010401302023-09-300001040130pets:MembershipFeesMemberpets:PartnerProgramMember2023-10-012023-12-310001040130pets:MembershipFeesMemberpets:PartnerProgramMember2023-04-012023-12-310001040130pets:ReorderMember2023-10-012023-12-31xbrli:pure0001040130pets:ReorderMember2022-10-012022-12-310001040130pets:NewOrderMember2023-10-012023-12-310001040130pets:NewOrderMember2022-10-012022-12-310001040130pets:MembershipFeesMember2022-10-012022-12-310001040130pets:ReorderMember2023-04-012023-12-310001040130pets:ReorderMember2022-04-012022-12-310001040130pets:NewOrderMember2023-04-012023-12-310001040130pets:NewOrderMember2022-04-012022-12-310001040130pets:MembershipFeesMember2022-04-012022-12-310001040130pets:PetCareRxIncMember2023-04-030001040130pets:PetCareRxIncMember2023-04-032023-04-030001040130pets:PetCareRxIncMember2022-04-012023-03-310001040130pets:PetCareRxIncMember2023-04-012023-12-310001040130pets:PetCareRxIncMember2022-04-012022-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2023-10-012023-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2022-10-012022-12-310001040130us-gaap:ConvertiblePreferredStockMember2023-10-012023-12-310001040130us-gaap:ConvertiblePreferredStockMember2022-10-012022-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2023-04-012023-12-310001040130pets:SharesIssuableUponVestingOfRestrictedStockMember2022-04-012022-12-310001040130us-gaap:ConvertiblePreferredStockMember2023-04-012023-12-310001040130us-gaap:ConvertiblePreferredStockMember2022-04-012022-12-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMember2023-04-012023-12-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2023-04-012023-12-310001040130pets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMemberus-gaap:RestrictedStockMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMemberpets:A2022EmployeePlanMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2023-04-012023-12-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMemberus-gaap:RestrictedStockMember2021-08-012021-08-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMembersrt:ChiefExecutiveOfficerMemberpets:PerformanceRestrictedStockMember2021-08-012021-08-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:RestrictedStockUnitsRSUMemberpets:FiscalYear2023Memberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:RestrictedStockUnitsRSUMemberpets:FiscalYear2024Memberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:PerformanceSharesMemberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:PerformanceSharesMemberpets:A2022EmployeePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMemberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:PerformanceSharesMemberpets:ShareBasedPaymentArrangementTrancheFourMemberpets:A2022EmployeePlanMembersrt:ChiefFinancialOfficerMember2023-06-012023-06-300001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2023-10-012023-12-310001040130pets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMemberus-gaap:RestrictedStockMember2023-10-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMemberpets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMember2023-10-012023-12-310001040130pets:EmployeeAndDirectorPlansMember2023-10-012023-12-310001040130pets:EmployeeAndDirectorPlansMember2022-10-012022-12-310001040130pets:EmployeeAndDirectorPlansMember2023-04-012023-12-310001040130pets:EmployeeAndDirectorPlansMember2022-04-012022-12-310001040130us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorPlansMember2023-12-310001040130us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorPlansMember2022-12-310001040130srt:MinimumMemberus-gaap:RestrictedStockMemberpets:EmployeeAndDirectorPlansMember2023-04-012023-12-310001040130srt:MaximumMemberus-gaap:RestrictedStockMemberpets:EmployeeAndDirectorPlansMember2023-04-012023-12-310001040130us-gaap:RestrictedStockMemberpets:EmployeeAndDirectorPlansMember2023-03-310001040130srt:MinimumMemberus-gaap:RestrictedStockMember2023-04-012023-12-310001040130srt:MaximumMemberus-gaap:RestrictedStockMember2023-04-012023-12-310001040130pets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMemberus-gaap:RestrictedStockMember2023-03-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMember2023-03-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2023-03-310001040130us-gaap:RestrictedStockMember2023-03-310001040130us-gaap:RestrictedStockMember2023-04-012023-12-310001040130pets:OutsideDirectorEquityCompensationRestrictedStockPlan2015DirectorPlanMemberus-gaap:RestrictedStockMember2023-12-310001040130pets:The2016EmployeeEquityCompensationRestrictedStockPlanMemberus-gaap:RestrictedStockMember2023-12-310001040130us-gaap:RestrictedStockMemberpets:A2022EmployeePlanMember2023-12-310001040130us-gaap:RestrictedStockMember2023-12-310001040130us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-03-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2023-10-012023-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2022-10-012022-12-310001040130us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-12-310001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2023-04-012023-12-310001040130srt:MinimumMember2023-04-012023-12-310001040130srt:MaximumMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMember2023-03-310001040130us-gaap:PerformanceSharesMember2023-04-012023-12-310001040130us-gaap:PerformanceSharesMember2023-12-310001040130us-gaap:PerformanceSharesMember2023-10-012023-12-310001040130us-gaap:PerformanceSharesMember2022-10-012022-12-310001040130us-gaap:PerformanceSharesMember2022-04-012022-12-310001040130pets:TollFreeTelephoneNumberMember2023-12-310001040130us-gaap:InternetDomainNamesMember2023-12-310001040130us-gaap:TradeNamesMember2023-12-310001040130us-gaap:CustomerRelationshipsMember2023-12-310001040130us-gaap:DevelopedTechnologyRightsMember2023-12-310001040130pets:PartnershipAgreementWithVetsterMember2023-12-310001040130pets:TollFreeTelephoneNumberMember2023-03-310001040130us-gaap:InternetDomainNamesMember2023-03-310001040130pets:PartnershipAgreementWithVetsterMember2023-03-310001040130pets:PartnershipAgreementWithVetsterMember2022-04-192022-04-190001040130pets:PartnershipAgreementWithVetsterMember2022-04-190001040130pets:PartnershipAgreementWithVetsterMember2023-10-032023-10-030001040130pets:PartnershipAgreementWithVetsterMember2023-10-030001040130us-gaap:CommonStockMember2023-03-310001040130us-gaap:AdditionalPaidInCapitalMember2023-03-310001040130us-gaap:RetainedEarningsMember2023-03-310001040130us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001040130us-gaap:RetainedEarningsMember2023-04-012023-06-300001040130us-gaap:CommonStockMember2023-06-300001040130us-gaap:AdditionalPaidInCapitalMember2023-06-300001040130us-gaap:RetainedEarningsMember2023-06-300001040130us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001040130us-gaap:RetainedEarningsMember2023-07-012023-09-300001040130us-gaap:CommonStockMember2023-09-300001040130us-gaap:AdditionalPaidInCapitalMember2023-09-300001040130us-gaap:RetainedEarningsMember2023-09-300001040130us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310001040130us-gaap:RetainedEarningsMember2023-10-012023-12-310001040130us-gaap:CommonStockMember2023-12-310001040130us-gaap:AdditionalPaidInCapitalMember2023-12-310001040130us-gaap:RetainedEarningsMember2023-12-310001040130us-gaap:CommonStockMember2022-03-310001040130us-gaap:AdditionalPaidInCapitalMember2022-03-310001040130us-gaap:RetainedEarningsMember2022-03-310001040130us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001040130us-gaap:RetainedEarningsMember2022-04-012022-06-300001040130us-gaap:CommonStockMember2022-06-300001040130us-gaap:AdditionalPaidInCapitalMember2022-06-300001040130us-gaap:RetainedEarningsMember2022-06-300001040130us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001040130us-gaap:RetainedEarningsMember2022-07-012022-09-300001040130us-gaap:CommonStockMember2022-09-300001040130us-gaap:AdditionalPaidInCapitalMember2022-09-300001040130us-gaap:RetainedEarningsMember2022-09-300001040130us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-310001040130us-gaap:RetainedEarningsMember2022-10-012022-12-310001040130us-gaap:CommonStockMember2022-12-310001040130us-gaap:AdditionalPaidInCapitalMember2022-12-310001040130us-gaap:RetainedEarningsMember2022-12-310001040130pets:PetCareRxIncMember2023-04-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 10-Q
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2023
or
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________ to _____________
Commission file number: 000-28827
________________________
PETMED EXPRESS, INC.
(Exact name of registrant as specified in its charter)
________________________
FLORIDA
65-0680967
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
420 South Congress Avenue, Delray Beach, Florida 33445
(Address of principal executive offices, including zip code)
(561) 526-4444
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $.001 per sharePETS
NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer o
Accelerated Filer x
Non-accelerated filer o
Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (defined in Rule 12b-2 of the Exchange Act).
Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 21,148,692 shares of Common Stock, $.001 par value per share, at April 15, 2024.



PART I - FINANCIAL INFORMATION
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical information, certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, our results of operations, financial position and our business outlook, business trends and other information, may be forward-looking statements. You can identify these forward-looking statements by the words "believes," "intends," "expects," “might,” "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," “potential,” "predicts," "estimates," "anticipates," “future,” “goal,” and variations of such words or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates and projections will result or be achieved, and actual future results may differ materially from what is expressed in or indicated by the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A, under the heading “Risk Factors,” in our Amendment No.1 on Form 10-K/A to our Annual Report on Form 10-K for the year ended March 31, 2023 (the “2023 Form 10-K/A”) filed with the Securities and Exchange Commission (“SEC”) on April 15, 2024, and under “Part II, Item 1A., Risk Factors” in this Quarterly Report on Form 10-Q. Such risk factors may be updated from time to time in our periodic filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and a reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.

We caution you that the risks, uncertainties and other factors referenced above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date of this Quarterly Report on Form 10-Q or as of the date they were made or as otherwise specified herein. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Investors and others should note that we use our websites (https://petmeds.com, https://petcarerx.com and https://www.investors.petmeds.com), as well as social media, press releases, SEC filings, public conference calls and webcasts, as channels of distribution of Company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, SEC filings, public conference calls and webcasts. The contents of our websites and social media posts, however, are not incorporated by reference into this Quarterly Report on Form 10-Q. Further, our references to website URLs in this filing are intended to be inactive textual references only.

NOTE REGARDING COMPANY REFERENCES

When used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, "PetMed Express," "PetMeds," "PetMed," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.
1


ITEM 1. FINANCIAL STATEMENTS.
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except for share and per share amounts)
December 31,
2023
March 31,
2023
(Unaudited)
(as restated)
ASSETS
Current assets:
Cash and cash equivalents$49,440 $104,086 
Accounts receivable, less allowance for doubtful accounts of $39 and $35, respectively
1,930 1,740 
Inventories - finished goods, net34,577 19,023 
Prepaid expenses and other current assets8,804 4,719 
Prepaid income taxes798 863 
Total current assets95,549 130,431 
Noncurrent assets:
Property and equipment, net26,811 26,178 
Intangible and other assets, net16,992 5,860 
Goodwill26,657  
Operating lease right-of-use assets, net1,626  
Deferred tax assets, net5,715 5,009 
Total noncurrent assets77,801 37,047 
Total assets$173,350 $167,478 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable$38,851 $25,208 
Sales tax payable24,172 26,113 
Accrued expenses and other current liabilities5,557 6,191 
Current lease liabilities752  
Deferred revenue3,068  
Total current liabilities72,400 57,512 
Long-term lease liabilities890  
Total liabilities73,290 57,512 
Commitments and contingencies (Note 9)  
Shareholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share
9 9 
Common stock, $.001 par value, 40,000,000 shares authorized; 21,160,739 and 21,084,302 shares issued and outstanding, respectively
21 21 
Additional paid-in capital23,473 18,277 
Retained earnings76,557 91,659 
Total shareholders' equity100,060 109,966 
Total liabilities and shareholders' equity$173,350 $167,478 
See accompanying notes to unaudited condensed consolidated financial statements.
2


PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME
(In thousands, except for share and per share amounts) (Unaudited)
Three Months Ended
December 31,
Nine Months Ended
December 31,
2023202220232022
(as restated)
(as restated)
Sales$65,317 $58,870 $214,560 $194,172 
Cost of sales47,434 43,632 154,089 140,819 
Gross profit17,883 15,238 60,471 53,353 
Operating expenses:
General and administrative13,425 10,425 41,098 29,669 
Advertising5,762 4,641 18,539 14,869 
Depreciation and amortization1,770 941 5,161 2,552 
Total operating expenses20,957 16,007 64,798 47,090 
(Loss) income from operations(3,074)(769)(4,327)6,263 
Other income:
Interest income, net136 299 481 11 
Other, net293 259 1,053 718 
Total other income429 558 1,534 729 
(Loss) income before provision for income taxes(2,645)(211)(2,793)6,992 
(Benefit) provision for income taxes(618)1 (345)1,636 
Net (loss) income$(2,027)$(212)$(2,448)$5,356 
Net (loss) income per common share:
Basic$(0.10)$(0.01)$(0.12)$0.26 
Diluted$(0.10)$(0.01)$(0.12)$0.26 
Weighted average number of common shares outstanding:
Basic20,425,28220,301,38420,380,26220,257,145
Diluted20,425,28220,301,38420,380,26220,339,064
Cash dividends declared per common share$ $0.30 $0.60 $0.90 
See accompanying notes to unaudited condensed consolidated financial statements.
3


PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)
Nine Months Ended
December 31,
20232022
(as restated)
Cash flows from operating activities:
Net (loss) income$(2,448)$5,356 
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization5,161 2,552 
Share based compensation5,196 4,987 
Deferred income taxes(436)(1,114)
Bad debt expense53 292 
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable(119)(324)
Inventories - finished goods(12,438)10,053 
Prepaid income taxes65 (927)
Prepaid expenses and other current assets(2,664)(771)
Operating lease right-of-use assets, net594  
Accounts payable7,929 (3,183)
Sales tax payable(1,942)2,291 
Accrued expenses and other current liabilities(1,258)(1,133)
Lease liabilities(577) 
Deferred revenue75  
Net cash (used in) provided by operating activities
(2,808)18,079 
Cash flows from investing activities:
Purchase of minority interest investment in Vetster(300)(5,000)
Acquisition of PetCareRx, net of cash acquired(35,859) 
Purchases of property and equipment(3,260)(3,329)
Net cash used in investing activities(39,419)(8,329)
Cash flows from financing activities:
Dividends paid(12,419)(18,402)
Net cash used in financing activities(12,419)(18,402)
Net decrease in cash and cash equivalents(54,646)(8,652)
Cash and cash equivalents, at beginning of period104,086 111,080 
Cash and cash equivalents, at end of period$49,440 $102,428 
Supplemental disclosure of cash flow information:
Cash paid for income taxes$43 $3,870 
Dividends payable in accrued expenses and other current liabilities$1,498 $1,079 
See accompanying notes to unaudited condensed consolidated financial statements.
4


PETMED EXPRESS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1: Restatement of Previously Issued Financial Statements

The unaudited condensed consolidated financial statements for the three and nine months ended December 31, 2022 (collectively, the "Affected Periods") have been restated to account for material misstatements related to the collection of sales taxes on sales of products and services to customers as further described below and the accounting treatment related to the deferred tax asset associated with the Company’s acquisition of PetCareRx in April 2023 (collectively, the “Misstatements”). The Company also restated all amounts impacted within the notes to the financial statements. A description of the adjustments and their impacts on the previously issued financial statements for each of the Affected Periods are included below. As a result of the Misstatements, our previously issued condensed consolidated financial statements for the Affected Periods should no longer be relied upon. In addition, we have filed our 2023 Form 10-K/A and an Amendment No. 1 to our Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2023 and September 30, 2023, to reflect the correction of the Misstatements.
Description of restatement adjustments
In the third quarter of fiscal year 2024, the Company, reviewed the accounting treatment related to its previously reported sales tax accruals as well as the accounting treatment related to the valuation of the deferred tax asset associated with the Company’s acquisition of PetCareRx in April 2023. As a result of this review, management determined that the Company incorrectly applied U.S. GAAP as it relates to the sales tax liability and improperly valued the deferred tax asset and goodwill included in its unaudited condensed consolidated financial statements for each of the Affected Periods.

We corrected the Misstatements relating to sales tax accruals by recording sales tax accruals as of the end of each of the Affected Periods using a legal liability approach under Accounting Standards Codification Topic 405, Liabilities. The sales tax accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) total potential interest and penalty assessments may be imposed, and (iii) the Company will not receive waivers of interest and penalties or other benefits under agreements it may obtain with jurisdictions from its outreach with voluntary disclosures. The Company expects to make adjustments to the sales tax liability in future periods as and if it obtains any waivers of interest and penalties or other benefits from its voluntary disclosures and as and if it obtains additional documentation from customers supporting exemption from sales tax.

In addition, we have corrected Misstatements relating to the deferred tax asset we recognized in connection with our acquisition of PetCareRx on April 3, 2023 (the “Acquisition”) as of the end of each of the Affected Periods. In the accounting for the Acquisition, it was determined that we incorrectly valued deferred tax assets associated with loss carryforwards of PetCareRx under section 382 of the Internal Revenue Code.
A summary of the impact of the adjustments described above relating to the Misstatements in each of the Affected Periods, is as follows:
December 31, 2022
Three Months EndedNine Months Ended
(in thousands)As previously reportedAs restatedAs previously reportedAs restated
Sales$58,870 $58,870 $194,451 $194,172 
Gross profit$15,238 $15,238 $53,632 $53,353 
(Loss) income from operations$(769)$(769)$5,682 $6,263 
Net (loss) income$(19)$(212)$5,335 $5,356 

5


December 31, 2022
Three Months EndedNine Months Ended
As previously reportedAs restatedAs previously reportedAs restated
Net (loss) income (numerator):
Net (loss) income$(19)$(212)$5,335 $5,356 
Shares (denominator):
Weighted average number of common shares outstanding used in basic computation20,301,38420,301,38420,257,14520,257,145
Common shares issuable upon vesting of restricted stock71,79471,794
Common shares issuable upon conversion of preferred shares10,12510,125
Shares used in diluted computation20,301,38420,301,38420,339,06420,339,064
Net (loss) income per common share:
Basic$ $(0.01)$0.26 $0.26 
Diluted$ $(0.01)$0.26 $0.26 
The restated unaudited interim financial information for the relevant unaudited interim financial statements for the quarterly period ended December 31, 2022 is also included below and identified in the Restatement Reconciliation Tables in the column entitled "Reference".
The categories of restatement adjustments and their impacts on previously reported financial statements are described below:
a.Sales Tax – Sales tax on sales of services to customers who were subject to sales tax, inclusive of total potential penalties and interest, that was not previously accrued by the Company is corrected by an increase to sales tax liabilities on the consolidated balance sheets. The effect of the adjustments on the consolidated statements of operations were recorded as a reduction to sales for the amount of tax, an increase to general and administrative expenses for accrued penalties and interest is included in other interest(expense) on the consolidated statements of operations.
b.Tax provision / accrual – Tax provisions, deferred tax assets and liabilities were adjusted based on restated net income and restated deferred assets valuation in connection with the acquisition of PetCareRx.
c.Deferred tax asset adjustment - Deferred tax asset recognized in connection with the acquisition of PetCareRx on April 3, 2023.
Consolidated Financial Statements - Restatement Reconciliation Tables
In light of the foregoing, in accordance with ASC 250, Accounting Changes and Error Corrections, we are restating the previously issued unaudited consolidated financial statements as of, and for the three and nine months ended December 31, 2022, to reflect the effects of the restatement adjustments and to make certain corresponding disclosures. In the following tables, we have presented a reconciliation of our consolidated balance sheets, statements of operations, and cash flows as previously reported for these prior periods to the restated and revised amounts.
6


Summary of Restatement - Consolidated Balance Sheets
December 31, 2022
As Previously ReportedRestatement AdjustmentsReferenceAs Restated
ASSETS
Current assets:
Cash and cash equivalents$102,428 $ $102,428 
Accounts receivable, less allowance for doubtful accounts of $40
1,944  1,944 
Inventories - finished goods22,402  22,402 
Prepaid expenses and other current assets5,637  5,637 
Prepaid income taxes1,608  1,608 
Total current assets134,019  134,019 
Noncurrent assets:
Property and equipment, net25,242  25,242 
Intangible and other assets5,860  5,860 
Deferred tax assets 4,493 b, c4,493 
Total noncurrent assets31,102 4,493 35,595 
Total assets$165,121 $4,493 $169,614 
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable$24,317 $ $24,317 
Sales tax payable 26,448 a26,448 
Accrued expenses and other current liabilities6,754 (2,775)a3,979 
Total current liabilities31,071 23,673 54,744 
Deferred tax liabilities465 (465)c 
Total liabilities31,536 23,208 54,744 
Commitments and contingencies   
Shareholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of $4 per share
9  9 
Common stock, $0.001 par value, 40,000,000 shares authorized; 21,077,077 shares issued and outstanding
21  21 
Additional paid-in capital16,647  16,647 
Retained earnings116,908 (18,715)a, b, c98,193 
Total shareholders' equity133,585 (18,715)114,870 
Total liabilities and shareholders' equity$165,121 $4,493 $169,614 

7


Summary of Restatement - Consolidated Statements of Operations
Three Months Ended December 31, 2022Nine Months Ended December 31, 2022
As Previously ReportedRestatement AdjustmentsRefer-enceAs RestatedAs Previously ReportedRestatement AdjustmentsRefer-enceAs Restated
Sales$58,870 $ $58,870 $194,451 $(279)a$194,172 
Cost of sales43,632  43,632 140,819  140,819 
Gross profit15,238  15,238 53,632 (279)53,353 
Operating expenses:
General and administrative10,425  10,425 30,529 (860)a29,669 
Advertising4,641  4,641 14,869  14,869 
Depreciation941  941 2,552  2,552 
Total operating expenses16,007  16,007 47,950 (860)47,090 
(Loss) income from operations(769) (769)5,682 581 6,263 
Other income:
Interest income, net708 (409)a299 1,213 (1,202)a11 
Other, net259  259 718  718 
Total other income967 (409)558 1,931 (1,202)729 
Income (loss) before provision for income taxes198 (409)(211)7,613 (621)6,992 
Provision for income taxes217 (216)b1 2,278 (642)b1,636 
Net (loss) income$(19)$(193)$(212)$5,335 $21 $5,356 
Net (loss) income per common share:
Basic$ $(0.01)$(0.01)$0.26 $ $0.26 
Diluted$ $(0.01)$(0.01)$0.26 $ $0.26 
Weighted average number of common shares outstanding:
Basic20,301,384  20,301,384 20,257,145  20,257,145 
Diluted20,301,384  20,301,384 20,339,064  20,339,064 
Cash dividends declared per common share$0.30 $ $0.30 $0.90 $ $0.90 








8


Summary of Restatement - Consolidated Cash Flow Statement
Nine Months Ended December 31, 2022
As Previously ReportedRestatement AdjustmentsReferenceAs Restated
Cash flows from operating activities:
Net income$5,335 $21 a$5,356 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation2,552  2,552 
Share based compensation4,987  4,987 
Deferred income taxes(471)(643)b(1,114)
Bad debt expense292  292 
(Increase) decrease in operating assets and increase (decrease) in liabilities:
Accounts receivable(324) (324)
Inventories - finished goods10,053  10,053 
Prepaid income taxes(927) (927)
Prepaid expenses and other current assets(771) (771)
Accounts payable(3,183) (3,183)
Sales tax payable 2,291 a2,291 
Accrued expenses and other current liabilities536 (1,669)a(1,133)
Net cash provided by operating activities18,079  18,079 
Cash flows from investing activities:
Purchase of minority interest investment in Vetster(5,000) (5,000)
Purchases of property and equipment(3,329) (3,329)
Net cash used in investing activities(8,329) (8,329)
Cash flows from financing activities:
Dividends paid(18,402) (18,402)
Net cash used in financing activities(18,402) (18,402)
Net (decrease) increase in cash and cash equivalents(8,652) (8,652)
Cash and cash equivalents, at beginning of year111,080  111,080 
Cash and cash equivalents, at end of year$102,428 $ $102,428 
Supplemental disclosure of cash flow information:
Cash paid for income taxes$3,870 $ $3,870 
Dividends payable in accrued expenses$1,079 $ $1,079 





9


Note 2:    Summary of Significant Accounting Policies
Organization
PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, is a leading direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats, and horses. The Company markets and sells directly to consumers through its websites, toll-free number, and mobile applications. The Company offers consumers an attractive option for obtaining pet medications, food, and supplies in terms of convenience, price, speed of delivery, and valued customer service.
Founded in 1996, the Company’s executive headquarters offices are located in Delray Beach, Florida. The Company’s fiscal year end is March 31, and references herein to fiscal 2024 or fiscal 2023 refer to the Company's fiscal years ending March 31, 2024 and 2023, respectively.
Basis of Presentation and Consolidation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at December 31, 2023, the Statements of (Loss) Income for the three and nine months ended December 31, 2023 and 2022, and Cash Flows for the nine months ended December 31, 2023 and 2022. The results of operations for the three and nine months ended December 31, 2023 are not necessarily indicative of the operating results expected for the fiscal year ending March 31, 2024. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in our 2023 Form 10-K/A. The unaudited condensed consolidated financial statements include the accounts of PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries. All significant intercompany transactions have been eliminated in consolidation.
Business Combinations
The Company accounts for its business combinations using the acquisition method of accounting in accordance with Accounting Standards Codification ("ASC") Topic 805 ("Business Combinations"). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in the Company’s unaudited condensed consolidated financial statements from the date of acquisition.

Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, the Company may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
Fair Value of Financial Instruments
The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.
10


Deferred Revenue
Deferred revenue is recorded when payments are received or due in advance of performing our service obligations and revenue is recognized over the service period. Deferred revenue represents prepayments of PetPlus memberships with PetCareRx, Inc. (“PetCareRx”). The total deferred revenue as of December 31, 2023 for these memberships was $3.1 million. Memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The membership fee is an annual charge and automatically renews one year from the initial enrollment date. The Company generally recognizes the revenue ratably over the term of the membership.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is not amortized but instead is tested for impairment annually on January 1, or more frequently if events or changes in circumstances indicate goodwill might be impaired. When testing goodwill for impairment, the Company has the option to choose whether it will apply a qualitative assessment first and then a quantitative assessment, if necessary, or to apply the quantitative assessment directly. The Company has concluded that it has one reporting unit and has assigned the entire balance of goodwill to this reporting unit.
Intangible Assets
The Company acquired definite-lived intangible assets in the acquisition (see Note 3) that will be amortized based on their estimated useful lives in accordance with ASC Topic 350 (“Goodwill and Other Intangible Assets”). These definite-lived intangible assets are being amortized over periods ranging from three to seven years. Acquired trade name is not being amortized and is subject to an annual review for impairment consistent with the existing intangible assets in fiscal 2024.
Leases
The Company accounts for leases in accordance with ASC Topic 842 ("Leases"). The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are reported as right-of-use (“ROU”) assets, current lease liabilities and long-term lease liabilities on the unaudited Condensed Consolidated Balance Sheets. The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.
Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company’s lease agreements do not contain any residual value guarantees.
Recent Accounting Pronouncements
The Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company's consolidated financial position, results of operations, or cash flows.
Note 3:    Revenue Recognition
In accordance with ASC Topic 606 ("Revenue from Contracts with Customers"), the Company generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, supplies, membership fees, and veterinary services. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product. Customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are based on historical patterns, however this is not considered a key judgment. Revenue is recognized when control transfers to the customer at the point in time at which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time
11


when the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership. Virtually all the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales.
Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.
Membership fees represent the amounts recognized periodically from two membership models. The first is the PetPlus membership for PetCareRx customers, the second is a partner membership provided through PetCareRx. These memberships provide discounted pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup which represent a single stand-ready performance obligation to provide these benefits. The PetPlus membership fee is an upfront annual charge and automatically renews one year from the initial enrollment date. The Company recognizes the revenue ratably over the term of the PetPlus membership which is generally one year. As shown in the following table, under the PetPlus program, the Company recognized $1.8 million and $5.3 million of previously deferred annual membership fees in the three and nine months ended December 31, 2023, respectively, and had $3.1 million of deferred revenue as of the quarter ended December 31, 2023 (amounts in millions).
2023
Deferred revenue, March 31,
$ 
Deferred revenue acquired with PetCareRx3.0 
Deferred memberships fees received2.0 
Deferred membership fee revenue recognized (1.8)
Deferred revenue, June 30,
3.2 
Deferred memberships fees received2.1 
Deferred membership fee revenue recognized(1.7)
Deferred revenue, September 30,
3.6 
Deferred memberships fees received1.3 
Deferred membership fee revenue recognized(1.8)
Deferred revenue, December 31,$3.1 
In addition to annual membership fees earned under the PetPlus program, the Company also earns membership fees on a month-to-month basis under its PetCareRx partner membership program. For the three and nine months ended December 31, 2023, membership fees earned under the partner program were $0.7 million and $2.0 million, respectively.
The Company has no material contract asset or liability balances at December 31, 2023 and March 31, 2023, respectively.
The Company disaggregates sales in the following categories: reorder sales vs new order sales vs membership fees. The following table illustrates sales in those categories:
Three Months Ended December 31,Increase (Decrease)
Revenue (in thousands)
2023%2022%
$
%
Reorder sales$57,682 88.3 %$53,316 90.6 %$4,366 8.2 %
New order sales5,189 7.9 %5,554 9.4 %(365)-6.6 %
Membership fees2,446 3.7 %  %2,446  %
Total net sales$65,317 100.0 %$58,870 100.0 %$6,447 11.0 %
12


Nine Months Ended December 31,Increase (Decrease)
Revenue (in thousands)
2023%2022%
$
%
(as restated)
Reorder sales$188,123 87.7 %$176,131 90.7 %$11,992 6.8 %
New order sales19,181 8.9 %18,041 9.3 %1,140 6.3 %
Membership fees7,256 3.4 %  %7,256  %
Total net sales$214,560 100.0 %$194,172 100.0 %$20,388 10.5 %

Note 4: Acquisition

On April 3, 2023, the Company acquired 100% of the issued and outstanding equity interests of PetCareRx, a New York corporation and a leading supplier of pet food, pet medications, and supplies. The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among the Company, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for the Company’s acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $36.1 million and was funded from the Company's cash on hand.

The acquisition of PetCareRx allowed the Company to significantly expand its product catalog, most notably in non-medication products, including food. In addition, PetCareRx brings increased distribution capability.

The Company recognized goodwill of approximately $26.7 million, which is calculated as the excess of the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. Goodwill recognized in the transaction represents synergies or scale achieved by significantly increasing the customer base without adding corresponding levels of additional overhead, the value of additional vendor relationships, including the food manufacturing relationships, a broader product catalog, and an assembled and experienced workforce. These items represent intangible assets that do not qualify for separate recognition. No goodwill is deductible for tax purposes.

The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of April 3, 2023, as calculated by an independent third-party firm. The selected rates of returns were chosen in consideration of the individual risk profiles of the assets, as well as the resulting weighted average return on assets. Intangible assets are considered to be riskier than the overall business, so the Company included a premium to the investment rate of return on the identified intangible discount rates.

The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of 12% based on the weighted average cost of capital.

As a result of the acquisition, the Company performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Refer to Note 11 for further discussion.

The table below outlines the purchase price allocation of the purchase for PetCareRx to the acquired identifiable assets, liabilities assumed and goodwill (in thousands):

13


Cash and cash equivalents$220 
Accounts receivable, net125 
Other receivables506 
Inventory3,116 
Other current assets835 
Property and equipment1,065 
Deferred tax assets, net270 
Goodwill26,657 
Intangible assets, net12,300 
Right of use assets2,220 
Other assets80 
Total assets47,394 
Accounts payable5,713 
Accrued liabilities131 
Deferred revenue2,993 
Other current liabilities258 
Lease liabilities2,220 
Total liabilities11,315 
Total purchase consideration$36,079 

The Company incurred a total of $1.8 million in acquisition related costs that were expensed as incurred and recorded in general and administrative expenses in the Company’s unaudited Condensed Consolidated Statements of (Loss) Income, of which $0.5 million was recorded in fiscal year 2023, and $1.3 million was recorded for the nine months ended December 31, 2023 These costs include banking, legal, accounting, and consulting fees related to the acquisition.

Supplemental Pro Forma Information (As Restated)

The supplemental pro forma financial information presented below is for illustrative purposes only, does not include the pro forma adjustments that would be required under Regulation S-X of the Exchange Act for pro forma financial information, is not necessarily indicative of the financial position or results of operations that would have been realized if the PetCareRx acquisition had been completed on April 1, 2022, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that the Company believes are reasonable under the circumstances.

The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the PetCareRx acquisition had occurred on April 1, 2022 to give effect to certain events that the Company believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:
a.A decrease in depreciation expense that would have been recognized due to acquired identifiable fixed assets;
b.A decrease in amortization expense that would have been recognized due to acquired identifiable intangible assets; and
c.A decrease in payroll costs and benefits.

The supplemental pro forma financial information for the prior period nine months ended December 31, 2022 is as follows (in thousands):

Nine Months Ended December 31, 2022
(unaudited)
Revenue$226,713 
Net income407 
14


Note 5:    Net (Loss) Income Per Share
In accordance with the provisions of ASC Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted and performance stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding.
The following is a reconciliation of the numerators and denominators of the basic and diluted net (loss) income per share computations for the periods presented (in thousands, except for share and per share amounts):
Three Months Ended December 31,Nine Months Ended
December 31,
2023202220232022
(as restated)
(as restated)
Net (loss) income (numerator):  
Net (loss) income$(2,027)$(212)$(2,448)$5,356 
Shares (denominator):  
Weighted average number of common shares outstanding used in basic computation20,425,282 20,301,384 20,380,262 20,257,145 
Common shares issuable upon vesting of restricted stock   71,794 
Common shares issuable upon conversion of preferred shares   10,125 
Shares used in diluted computation20,425,282 20,301,384 20,380,262 20,339,064 
Net (loss) income per common share:
Basic$(0.10)$(0.01)$(0.12)$0.26 
Diluted$(0.10)$(0.01)$(0.12)$0.26 
For the three months ended December 31, 2023 and 2022, 825,825 and 243,604 shares issuable upon vesting of restricted stock and 10,125 and zero shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share. For the nine months ended December 31, 2023 and 2022, 837,084 and 243,604 shares issuable upon vesting of restricted stock and 10,125 and zero shares issuable upon conversion of preferred shares, respectively, were excluded from the computation of diluted net (loss) income per common share, as their inclusion would have had an anti-dilutive effect on diluted net (loss) income per common share.
Note 6:    Stock-Based Compensation
The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Compensation - Stock Compensation”). The Company had 961,973 common shares issued under the 2016 Employee Equity Compensation Restricted Stock Plan (the “2016 Employee Plan”) (which 2016 Employee Plan was succeeded by the 2022 Employee Plan in April 2023, and no further awards will be granted under the 2016 Employee Plan), 89,742 common shares issued under the 2022 Employee Equity Compensation Plan (as amended) (the “2022 Employee Plan”), and 225,251 common shares issued under the 2015 Outside Director Equity Compensation Plan (as amended) (the “2015 Director Plan”). At December 31, 2023, all shares were issued with service-based vesting conditions which vest subject to the employee's continued employment with the Company or the director’s continued directorship with the Company through the applicable vesting date. The Company records stock-based compensation expense for these awards on a straight-line basis over the requisite service period. The Company reverses stock-based compensation expense previously recorded upon forfeiture of unvested awards except for performance restricted shares with a market condition issued to the Chief Executive Officer (“CEO”) and performance stock units (“PSUs”) with a market condition issued to the Chief
15


Financial Officer (“CFO”) as described in the following paragraphs. Stock-based compensation expense previously recorded for these awards will not be reversed if the awards are forfeited.
In June 2023, the Board of Directors amended and restated the 2015 Director Plan and the 2022 Employee Plan (collectively, the "Plans") to include the ability to grant restricted stock units ("RSUs") and performance stock units ("PSUs") under the Plans. The amendments and restatement of the Plans did not increase the maximum number of shares of common stock that may be awarded under the Plans. At December 31, 2023, the Company had 55,380 RSUs and 12,000 PSUs granted under the 2022 Employee Plan and 30,000 RSUs granted under the 2015 Director Plan.

In August 2021, the Company issued 90,000 restricted shares and 510,000 restricted shares with a market condition to the Company’s CEO, in accordance with the CEO’s employment agreement, under the 2016 Employee Plan. The restricted shares with a market condition vest based on achieving absolute stock hurdles within the three-year period from the grant date. If the shares meet the absolute stock price hurdle, they will only vest on the third anniversary of the date of grant subject to the CEO’s continued employment with the Company through such date. As of December 31, 2023, none of the performance stock hurdles were met.
In June 2023, the Company granted the Company's CFO 11,750 RSUs under the 2022 Employee Plan, of which 3,750 RSUs were awarded in recognition of the CFO’s contributions during fiscal year 2023 and the remaining 8,000 awarded as a part of the equity award cycle for fiscal year 2024. One-third of the RSUs will vest on each of the first three anniversaries of the date of grant, subject to the CFO’s continued employment with the Company through the applicable vesting date, with any unvested RSUs being forfeited upon the CFO ceasing to be an employee of the Company. Also in June 2023, the CFO was awarded 8,000 PSUs with a market condition. The CFO will earn shares of our common stock pursuant to the PSUs based on the Company’s total shareholder return (“TSR”) relative to the S&P 600 Specialty Retail Index (“Index”) over an overall three-year performance period consisting of the 2024 through 2026 fiscal years, as follows:

100% of the target number of shares, which is 8,000 shares, will be earned if the Company’s TSR is equal to or greater than the 75th percentile of the Index (the “maximum target payout”);
50% of the target number of shares, which is 4,000 shares, will be earned if the Company’s TSR is equal to at least the 50th percentile of the Index;
25% of the target number of shares, which is 2,000 shares, will be earned if the Company’s TSR is equal to at least the 25th percentile of the Index (the “minimum threshold”);
No shares will be earned if the TSR is less than the 25th percentile of the Index, and the payout is capped at 2,000 shares if absolute TSR is negative, regardless of relative position to the Index; and
Linear scaling will be used to determine the number of shares earned for performance between the maximum target payout level and the minimum threshold payout level.
The Company issued 14,000 shares of restricted stock to employees under the 2022 Employee Plan during the three months ended December 31, 2023. The Company issued zero shares of restricted stock and zero RSUs to board members under the 2015 Director Plan during the quarter ended December 31, 2023. For the quarters ended December 31, 2023 and 2022, the Company recognized $1.7 million and $1.8 million, respectively, of compensation expense related to the 2016 Employee Plan, 2022 Employee Plan, and 2015 Director Plan. For the nine months ended December 31, 2023 and 2022, the Company recognized $5.2 million and $5.0 million, respectively, of compensation expense related to the 2016 Employee Plan, 2022 Employee Plan, and 2015 Director Plan. At December 31, 2023 and 2022 there was $6.1 million and $10.6 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the next one to three years. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the Company’s unaudited Consolidated Statements of (Loss) Income, and the offset is included in the additional paid-in capital line item of the Company’s unaudited Condensed Consolidated Balance Sheets. As of December 31, 2023 and March 31, 2023, there were 728,446 and 752,829 non-vested restricted shares issued and outstanding, respectively.
Restricted Stock Awards
The fair value assigned to restricted stock awards is the market price of the Company’s stock at the grant date. The vesting period range from one to three years. Restricted stock award activity under the 2016 Employee Plan, 2022 Employee Plan, and 2015 Director Plan was as follows:
16


 2015 Director Plan  2016 Employee Plan  2022 Employee Plan  Total  Weighted-Average Grant Date Fair Value
Non-vested restricted stock outstanding at March 31, 202368,629 684,200  752,829 $27.73 
Granted and issued1,623 12,400 89,742 103,765 $14.75 
Vested(28,585)(72,235) (100,820)$26.57 
Forfeited(17,127)(10,201) (27,328)$24.67 
Balance at December 31, 202324,540 614,164 89,742 728,446 $26.16 
Restricted Stock Units
The fair value assigned to RSUs is the market price of the Company’s stock on the grant date. The vesting period for employees and members of the Board of Directors ranges from one to three years.

RSU activity under the Plans was as follows:
RSUsWeighted-Average
 Grant Date
 Fair Value Per RSU
Balance at March 31, 2023$ 
Granted 85,380$12.58 
Vested and issued$ 
Forfeited(300)$ 
Balance at December 31, 202385,080$12.57 

The total grant-date fair value of RSUs granted during the three months ended December 31, 2023 and 2022 was zero for both periods. The total grant-date fair value of RSUs granted during the nine months ended December 31, 2023 and 2022 was $1.1 million and zero, respectively.

For the three months ended December 31, 2023 and 2022, the Company recorded stock-based compensation related to RSUs of $0.1 million and zero, respectively. For the nine months ended December 31, 2023 and 2022, the Company recorded stock-based compensation related to RSUs of $0.2 million and zero, respectively.

Performance Stock Units

The fair value assigned to PSUs is determined using the market price of the Company’s stock on the grant date for awards with a performance condition, and by using a Monte Carlo simulation for awards with a market condition. PSUs with a performance condition vest over one year. PSUs with a market condition vest over three years. Stock-based compensation costs associated with PSUs with a performance condition are re-assessed each reporting period based upon the estimated performance attainment on the reporting date until the performance conditions are met. The ultimate number of shares of common stock that are issued to an employee is the result of the actual performance of the Company at the end of the performance period compared to the performance targets and generally ranges from 0% to 200% of the initial PSU grant.

17


PSU activity under the Plans was as follows:
PSUsWeighted-Average
 Grant Date
 Fair Value Per PSU
Balance at March 31, 2023$ 
Granted 12,000$11.35 
Vested and issued$ 
Forfeited$ 
Performance adjustment$ 
Balance at December 31, 202312,000$11.35 

The total grant-date fair value of PSUs granted during the three months ended December 31, 2023 and 2022 was zero for both periods. The total grant-date fair value of PSUs granted during the nine months ended December 31, 2023 and 2022 was $0.1 million and zero, respectively.

For the three months ended December 31, 2023 and 2022, the Company recorded stock-based compensation related to PSUs of zero for both periods. For the nine months ended December 31, 2023 and 2022, the Company recorded stock-based compensation related to PSUs of zero for both periods.

Note 7:    Fair Value
The Company carries cash and cash equivalents at fair value in the unaudited Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurement”) establishes a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.
Level 3 - Unobservable inputs which are supported by little or no market activity.
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At December 31, 2023 and March 31, 2023, the Company had invested the majority of its $49.4 million and $104.1 million cash and cash equivalents balance in money market funds which are classified within Level 1.

18


Note 8: Intangible and Other Assets, Net

Intangible assets and other assets, net consisted of the following (in thousands):

Useful LifeGross ValueAccumulated AmortizationNet Carrying ValueWeighted Average Remaining Useful Life (Years)
December 31, 2023
Intangible Assets
Toll-free telephone numberIndefinite$375 $– $375 Indefinite
Internet domain namesIndefinite485 – 485 Indefinite
Trade Names - PetCareRxIndefinite2,600 – 2,600 Indefinite
Customer Relationships -PetCareRx7 years6,700 (718)5,982 6.25
Developed Technology - PetCareRx3 years3,000 (750)2,250 2.25
$13,160 $(1,468)$11,692 
Other Assets
Initial minority interest investment in VetsterN/A5,300 – 5,300 N/A
Balance December 31, 2023$18,460 $(1,468)$16,992 
March 31, 2023
Intangible Assets
Toll-free telephone numberIndefinite$375 $– $375 Indefinite
Internet domain namesIndefinite485 – 485 Indefinite
$860 $– $860 
Other Assets
Initial minority interest investment in VetsterN/A5,000 – 5,000 N/A
Balance March 31, 2023$5,860 $ $5,860 

Amortization expense for intangible assets was $0.5 million and zero for the three months ended December 31, 2023 and 2022, respectively. Amortization expense for intangible assets was $1.5 million and zero for the nine months ended December 31, 2023 and 2022, respectively. The indefinite life intangibles are not being amortized and are subject to an annual review for impairment in accordance with the ASC Topic 350 (“Goodwill and Other Intangible Assets”).
On April 19, 2022, the Company engaged in a three-year partnership agreement with Vetster Inc. (“Vetster”), a Canadian veterinary telehealth company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company became the exclusive e-commerce provider for Vetster, and Vetster became the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the cost basis and the investment will be evaluated periodically for any impairment. On October 3, 2023, the Company purchased additional shares in Vetster in the amount of $0.3 million. This increases the minority interest investment disclosed in Note 7 to $5.3 million. Following this round, the Company’s minority ownership changed to approximately 4.8% of Vetster’s outstanding shares.

Note 9: Leases
The Company’s leasing activities primarily consist of real estate leases acquired during the acquisition of PetCareRx for use in the business operations. The leases had initial terms ranging from 5 years to 10 years. Some of the initial lease terms have already matured and the remaining leases have maturity dates ranging from fiscal year 2024 to 2028. The Company assesses whether each lease is an operating lease or a finance lease at the lease commencement date. The Company does not have any material leases, individually or in the aggregate, classified as a finance lease.
19


Variable Lease Costs
Certain of the Company’s leases require payments for taxes, insurance, and other costs applicable to the property, in addition to the minimum lease payment. These costs are considered variable costs which are based on actual expenses incurred by the lessor. Therefore, these amounts are not included in the calculation of the right-of-use assets and lease liabilities.
The Company has lease agreements which provide for fixed and scheduled escalations, which are included in the calculation of the right-of-use assets and lease liabilities.
Options to Extend or Terminate Leases
The Company’s leases may contain an option to extend the lease term for periods from one to five years The exercise of lease renewal options is at the Company’s sole discretion. If it is reasonably certain that the Company will exercise such options, the periods covered by such options are included in the lease term and are recognized as part of the Company’s right-of-use assets and lease liabilities. The Company’s leases do not generally contain options to early terminate.
Other Lease items
The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
The Company's operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities on the accompanying unaudited Condensed Consolidated Balance Sheets.
Discount Rate and Lease Term
As of December 31, 2023, the weighted average remaining lease term and discount rate for the Company’s operating leases were 3.1 years and 3.8%, respectively. As the rate implicit in the lease is generally not readily determinable for the Company’s operating leases, the Company uses its estimated incremental borrowing rate based on the information available at the date of acquisition, April 3, 2023, in determining the present value of future payments.
Lease Costs and Activity
The Company’s lease costs as recorded in the general and administrative costs and activity for the three and nine months ended are as follows (in thousands):
Lease costThree months ended December 31, 2023Nine Months Ended December 31, 2023
Operating lease cost - fixed$215 $646 
Operating lease costs - variable15 43 
Total lease cost$230 $689 
Supplemental cash flow information for the three and nine months ended are as follows (in thousands):
Three months ended December 31, 2023Nine Months Ended December 31, 2023
Cash paid for the amounts included in the measurement of operating lease liabilities$211 $630 
Right-of-use assets obtained in exchange for new operating lease liabilities as a result of acquisition$2,220 $2,220 
Maturity of Lease Liabilities
The maturity of the Company’s lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating lease liabilities recognized on the Company’s unaudited Condensed Consolidated Balance Sheet as of December 31, 2023 were as follows (in thousands):
20


December 31, 2023
Three months ending March 31, 2024$202 
2025501 
2026488 
2027502 
202842 
Total lease payments1,735 
Less: Imputed Interest(92)
Present value of lease liabilities$1,643 
Note 10:    Commitments and Contingencies
Legal Matters and Routine Proceedings
The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company also intends to vigorously defend its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred. From time to time, the Company may be involved in and subject to disputes and legal proceedings, as well as demands, claims and threatened litigation that arise in the ordinary course of its business. These proceedings may include allegations involving business practices, infringement of intellectual property, employment or other matters. The ultimate outcome of any legal proceeding is often uncertain, there can be no assurance that the Company will be successful in any legal proceeding, and unfavorable outcomes could have a negative impact on our results of operations and financial condition. In accordance with ASC Topic 450-20 ("Loss Contingencies"), the Company records a liability in its financial statements for these matters when a loss is known or considered probable and the amount can be reasonably estimated. The Company reviews the status of each significant matter each accounting period as additional information is known and adjusts the loss provision when appropriate. If a matter is both probable to result in a liability and the amounts of loss can be reasonably estimated, the Company estimates and discloses the possible loss or range of loss to the extent necessary to make the financial statements not misleading. If the loss is not probable and cannot be reasonably estimated, a liability is not recorded in the Company’s financial statements. Gain contingencies are not recorded until they are realized. Legal costs related to any legal matters are expensed as incurred.

21


Note 11:     Changes in Shareholders Equity (As Restated):
Changes in Shareholders’ Equity for the nine months ended December 31, 2023 is summarized below (in thousands):
Common StockAdditional
Paid-In
Capital
Retained
Earnings
Beginning balance at March 31, 2023 (as restated):$21 $18,277 $91,659 
Share based compensation— 1,760 — 
Dividends declared— — (6,346)
Net loss— — (1,136)
Ending balance at June 30, 2023 (as restated):$21 $20,037 $84,177 
Share based compensation— 1,728 — 
Dividends declared— — (6,308)
Net loss— — 715 
Ending balance at September 30, 2023 (as restated):$21 $21,765 $78,584 
Share based compensation— 1,708 — 
Net loss
— — (2,027)
Ending balance at December 31, 2023:$21 $23,473 $76,557 
Changes in Shareholders’ Equity for the nine months ended December 31, 2022 is summarized below (in thousands):
Common StockAdditional
Paid-In
Capital
Retained
Earnings
Beginning balance at March 31, 2022 (as restated):$21 $11,660 $111,760 
Share based compensation— 1,536 — 
Dividends declared— — (6,297)
Net income— — 2,687 
Ending balance at June 30, 2022 (as restated):$21 $13,196 $108,150 
Share based compensation— 1,681 — 
Dividends declared— — (6,307)
Net income— — 2,881 
Ending balance at September 30, 2022 (as restated):$21 $14,877 $104,724 
Share based compensation— 1,770 — 
Dividends declared— — (6,319)
Net loss— — (212)
Ending balance at December 31, 2022 (as restated):$21 $16,647 $98,193 
There were no shares of common stock that were purchased or retired in the nine months ended December 31, 2023 or 2022. At December 31, 2023, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.
Note 12: Income Taxes (As Restated)
For the three months ended December 31, 2023 and 2022, the Company recorded an income tax benefit of approximately $0.6 million and an income tax provision of approximately $1.0 thousand, respectively, and for the nine months ended December 31, 2023 and 2022 the Company recorded an income tax benefit of approximately $0.3 million and an income tax provision of approximately $1.6 million, respectively. The decrease in the income tax provision for the
22


three and nine months ended December 31, 2023 is related to the gain on settlement of sales tax liability cases. The effective tax rate for the three months ended December 31, 2023 was approximately 23.4%, compared to approximately (0.5)% for the three months ended December 31, 2022, and the effective tax rate for the nine months ended December 31, 2023 was approximately 12.4% compared to approximately 23.4% for the nine months ended December 31, 2022. The decrease in the effective tax rate for the three and nine months ended December 31,2023 is related to the deduction of permanent differences from the gain on settlement of sales tax liability cases.
Under Internal Revenue Code Section 382, if a corporation undergoes an “ownership change”, the corporation’s ability to use its pre-change net operating loss and tax credit carryforwards to offset its post-change income and tax liabilities may be limited. Generally, an ownership change occurs when the equity ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points over their lowest ownership percentage in a testing period (typically three years). On April 3, 2023, 100% of the issued and outstanding stock of PetCareRx was acquired by the Company. The merger triggered an ownership change of PetCareRx within the meaning of Section 382.

As a result of the acquisition, the Company performed a Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Any limitation may result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce the Company's gross deferred tax assets. As of April 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0 million of net operating losses and $1.9 million of disallowed interest expense. The results of the preliminary Section 382 analysis determined the net operating losses and disallowed interest expense in total, would be limited and reduced to approximately $14.5 million.

23


ITEM 2.    MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2023, and our 2023 Form 10-K/A.
Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of our 2023 Form 10-K/A under the heading “Risk Factors.” A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

When used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise indicates, "PetMed Express," "PetMeds," "PetMed," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.
Executive Summary
PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats and horses. PetMeds markets and sells directly to consumers through its websites, toll-free numbers, and mobile applications. We offer consumers an attractive option for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.
Founded in 1996, our executive headquarters offices are located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444. We have a March 31 fiscal year end.
Presently, our product line includes approximately 15,000 of the most popular pet medications, health products, food and supplies for dogs, cats, and horses. Approximately 9,000 of these items were part of the April 2023 acquisition of PetCareRx.
We market our products through national advertising campaigns and social media which aim to increase the recognition of the “PetMeds®” brand name, increase traffic on our websites at www.petmeds.com and www.petcarerx.com, acquire new customers, and maximize repeat purchases. Our sales consist of products sold mainly to retail consumers. The average purchase was approximately $93 for the quarter ended December 31, 2023, approximately $90 for the quarter ended December 31, 2022, approximately $95 for the nine months ended December 31, 2023 and approximately $93 for the nine months ended December 31, 2022.

Restatement

As described in the Note 1 of “Notes to Condensed Consolidated Financial Statements,” we have restated our consolidated financial statements and Item 2. Management’s Discussion of Financial Condition and Results of Operations for the three and nine months ended December 31, 2022.
Critical Accounting Policies
Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our condensed consolidated financial statements and the data used to prepare them. Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of
24


current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.
Revenue recognition
We account for revenue under Accounting Standards Codification ("ASC") Topic 606 ("Revenue from Contracts with Customers"). The Company generates revenue by selling prescription and non-prescription pet medication products, pet food, supplements, supplies, membership fees, and veterinary services. Certain pet supplies offered on our website are drop shipped to customers. We consider ourself the principal in the arrangement because we control the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however this is not considered a key judgment. There are no amounts excluded from the variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time where we have a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.
Outbound shipping and handling fees are an accounting policy election and are included in sales as we consider ourself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. Virtually all of our sales are paid by credit cards and we usually receive the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales.
Membership fees represent the amounts recognized periodically from the PetPlus memberships provided through PetCareRx. In addition to annual membership fees earned under the PetPlus program, we also earns membership fees on a month-to-month basis as earned under our monthly partner program. Memberships provide wholesale pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The PetPlus membership fee is an annual charge and automatically renews one year from the initial enrollment date. We recognize the revenue ratably over the term of the membership which is generally one year.
We maintain an allowance for doubtful accounts for losses that we estimate will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. We determine our estimates of the uncollectibility of accounts receivable by analyzing historical and current bad debts and economic trends in compliance with the provisions of ASC Topic 326 ("Financial Instruments - Credit Losses"). The allowance for doubtful accounts was approximately $39 thousand at December 31, 2023, compared to $35 thousand at March 31, 2023.
Business Combinations
We account for our business combinations using the acquisition method of accounting in accordance with ASC Topic 805 ("Business Combinations"). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in our unaudited condensed consolidated financial statements from the date of acquisition.

Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, we may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by us are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.

25


Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the attached unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.
Acquisition

On April 3, 2023, we acquired 100% of the issued and outstanding equity interests of PetCareRx, Inc. (“PetCareRx”), a New York corporation and a leading supplier of pet food, pet medications, and supplies. The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among us, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for our acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $36.1 million and was funded from our cash on hand.

The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of 12% based on the weighted average cost of capital.

Income taxes
We account for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in our condensed consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.
As a result of the acquisition, we performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Any limitation may result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce our gross deferred tax assets. As of April 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0 million of net operating losses and $1.9 million of disallowed interest expense. The results of the Section 382 analysis determined the net operating loss and disallowed interest expense in total, would be limited and reduced to $14.5 million.
Economic Conditions, Challenges, and Risks

Macroeconomic factors, including inflation, increased interest rates, significant capital market and supply chain volatility, and global economic and geopolitical developments, have direct and indirect impacts on our results of operations that are difficult to isolate and quantify. In addition, rising fuel, utility, and food costs, rising interest rates, and recessionary fears may impact customer demand and our ability to forecast consumer spending patterns. We also expect the current macroeconomic environment and enterprise customer cost optimization efforts to impact our revenue growth rates. We expect some or all of these factors to continue to impact our operations for the remainder of fiscal 2024.
26


Results of Operations
The following should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in our unaudited Condensed Consolidated Statements of (Loss) Income:
Three Months Ended
December 31,
Nine Months Ended
December 31,
2023202220232022
(as restated)
(as restated)
Sales100.0 %100.0 %100.0 %100.0 %
Cost of sales72.6 74.1 71.8 72.5 
Gross profit27.4 25.9 28.2 27.5 
Operating expenses:
General and administrative20.6 17.7 19.2 15.3 
Advertising8.8 7.9 8.6 7.7 
Depreciation and amortization2.7 1.6 2.4 1.3 
Total operating expenses32.1 27.2 30.2 24.3 
(Loss) income from operations(4.7)(1.3)(2.0)3.2 
Total other income0.7 0.9 0.7 0.4 
Income (loss) before provision for income taxes
(4.0)(0.4)(1.3)3.6 
(Benefit) provision for income taxes(0.9)— (0.2)0.8 
Net (loss) income(3.1)%(0.4)%(1.1)%2.8 %
Non-GAAP Financial Measures
Adjusted EBITDA
To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense, depreciation and amortization, income tax provision, interest income (expense), and other non-operational expenses. We have provided reconciliations below of net income to adjusted EBITDA, the most directly comparable GAAP financial measures.
We have included adjusted EBITDA herein because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other non-operational expenses, including the investment banking fee related to the Vetster partnership,
27


acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
Adjusted EBITDA does not reflect certain non operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers.
Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.
Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.
The following tables present a reconciliation of net income, the most directly comparable GAAP measure, to adjusted EBITDA for each of the periods indicated:
Three Months Ended
Increase (Decrease)
($ in thousands, except percentages)December 31,
2023
December 31,
2022
$
%
(as restated)
Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA:
Net loss$(2,027)$(212)$(1,815)856 %
Add (subtract):
Share-based Compensation1,707 1,770 (63)(4)%
Income Taxes(618)(619)n/m
Depreciation and Amortization1,770 941 829 88 %
Interest (Income) Expense, Net (1)(136)(29